Diagnosing aggressive prostate cancer by spectroscopic photoacoustic tomography

通过光谱光声断层扫描诊断侵袭性前列腺癌

• 批准号: 8832711
• 负责人: Ji-Xin Cheng
• 金额: $ 21.3万
• 依托单位: VIBRONIX, INC.
• 依托单位国家: 美国
• 财政年份: 2015
• 资助国家: 美国
• 起止时间: 2015-05-01 至 2016-10-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8832711
• 关键词: Address; Adult; Algorithms; Appearance; Biological Markers; Blood; Businesses; Cancer Detection; Cancer Patient; Cancerous; Cessation of life; Chemicals; Cholesterol Esters; Clinic; Clinical; Color; Diagnosis; Diagnostic Procedure; Digital Rectal Examination; Evaluation; Feasibility Studies; Foundations; Gland; Gleason Grade for Prostate Cancer; Goals; Grant; Histology; Image; Imaging technology; Indiana; Malignant Neoplasms; Malignant neoplasm of prostate; Maps; Measurement; Measures; Methods; Modality; Molecular; Near-Infrared Spectroscopy; Needle biopsy procedure; Operative Surgical Procedures; Pathology; Patients; Pattern; Phase; Physicians; Procedures; Prostate; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms; Proteins; Research; Resolution; Sampling; Screening for Prostate Cancer; Small Business Technology Transfer Research; Specificity; System; Technology; Testing; Tissues; Transrectal Ultrasound; Tumor Volume; Ultrasonic Transducer; Ultrasonography; Universities; Urogenital Cancer; Urology; accurate diagnosis; base; cancer diagnosis; cancer imaging; chemical bond; design; in vivo; male; medical schools; men; miniaturize; minimally invasive; phase 2 study; photoacoustic imaging; prevent; professor; public health relevance; tomography; tumor

DESCRIPTION (provided by applicant): Prostate cancer (PCa) is the No. 2 killer among male cancer patients. The ultimate test is based on transrectal ultrasound guided needle biopsy and histological examination of fixed prostate tissues. This conventional diagnostic procedure is invasive, missing 30% cases of cancer due to small sampling volume. Moreover, it leads to an overtreatment of patients due to low specificity in diagnosing aggressive cancers. To address this pressing need, Vibronix, Inc. and its research partners at Purdue University and Indiana University School of Medicine propose to develop a spectroscopic vibrational photoacoustic tomography (VPAT) system for PCa diagnosis using cholesteryl ester accumulation as biomarker. As an Indiana-based small business, Vibronix, Inc.'s long-term goal is to bring the VPAT technology from bench top to bedside. The central hypothesis of this STTR project is that the VPAT system can measure the size of the tumor in intact prostate tissue. Vibronix, Inc. along with its research partners have formed an interdisciplinary team to test this hypothesis. Dr. Ji-Xin Cheng (PI) the first to demonstrate CE accumulation as a marker for PCa. His lab also demonstrated the first VPAT system 6. Dr. Liang Cheng (MD) is a professor in Department of Pathology in Indiana University School of Medicine (IUSM) and will perform pathological grading of the prostatectomy samples. Dr. Timothy Masterson (MD) is an Assistant Professor of Urology and specializes in the treatment of adult genitourinary cancers. The proposed hypothesis can be tested through the following specific aims: (1) Demonstrate a miniaturized VPAT system with an imaging depth of 3 cm. (2) Demonstrate spectroscopic VPAT imaging of intact prostate gland using CE as a biomarker to differentiate normal and cancerous prostate tissues, and the measurement of the tissue volume. Deliverable: Upon successful design and evaluation of the transrectal spectroscopic VPAT system, we will have generated a new imaging technology for measure the prostate tumor volume in an intact prostate gland using CE as a biomarker. This advance will pave the foundation for a phase II study in which in vivo VPAT imaging will be performed and CE accumulation will be correlated with aggressiveness of PCa. Eventually, our VPAT technology, in a minimally invasive manner, would assist a physician to diagnose PCa objectively and to decide whether prostatectomy surgery is needed.

描述（申请人提供）：前列腺癌（PCa）是男性癌症患者的第二大杀手。最终测试基于经直肠超声引导的针活检和固定前列腺组织的组织学检查。这种传统的诊断程序是侵入性的，由于采样量小，会漏掉 30% 的癌症病例。此外，由于诊断侵袭性癌症的特异性较低，它会导致患者过度治疗。为了满足这一迫切需求，Vibronix, Inc. 及其普渡大学和印第安纳大学医学院的研究合作伙伴提议开发一种光谱振动光声断层扫描 (VPAT) 系统，使用胆固醇酯积累作为生物标志物来诊断前列腺癌。作为一家总部位于印第安纳州的小型企业，Vibronix, Inc. 的长期目标是将 VPAT 技术从实验室带到临床。该 STTR 项目的中心假设是 VPAT 系统可以测量完整前列腺组织中肿瘤的大小。 Vibronix, Inc. 与其研究合作伙伴组成了一个跨学科团队来检验这一假设。 Ji-Xin Cheng 博士 (PI) 第一个证明 CE 积累可作为 PCa 的标志物。他的实验室还展示了第一个 VPAT 系统 6。梁成博士（MD）是印第安纳大学医学院（IUSM）病理学系的教授，将对前列腺切除样本进行病理分级。 Timothy Masterson 博士（医学博士）是泌尿外科助理教授，专门研究成人泌尿生殖系统癌症的治疗。所提出的假设可以通过以下具体目标进行检验：（1）演示成像深度为3厘米的小型化VPAT系统。 (2) 展示完整前列腺的光谱 VPAT 成像，使用 CE 作为生物标志物来区分正常和癌性前列腺组织，并测量组织体积。可交付成果：在成功设计和评估经直肠光谱 VPAT 系统后，我们将开发出一种新的成像技术，用于使用 CE 作为生物标志物来测量完整前列腺中的前列腺肿瘤体积。这一进展将为 II 期研究奠定基础，其中将进行体内 VPAT 成像，并将 CE 积累与 PCa 的侵袭性相关联。最终，我们的VPAT技术以微创方式帮助医生客观诊断PCa并决定是否需要进行前列腺切除手术。